Street Calls of the Week
CAMBRIDGE - EDX Medical Group plc (AQSE:EDX) has launched a new testicular cancer testing service called TC100, according to a press release statement issued Tuesday.
The service, which the company describes as the most advanced available in the UK, is based on a blood sample that includes micro-RNA biomarker reporting alongside three standard serum biomarkers used in NHS testicular cancer treatment pathways: Alpha-fetoprotein (AFP), Human Chorionic Gonadotrophin (HCG), and Lactate Dehydrogenase (LDH).
According to the company, the test has shown high accuracy rates in detecting early signs of testicular cancer and monitoring cancer recurrence in survivors. The company reports that over 30 clinical study reports have confirmed the accuracy of the proprietary micro-RNA biomarker included in the service.
Dr. Mike Hudson, CEO of EDX Medical, said the TC100 service "includes and significantly enhances the usefulness of the current confirmatory NHS biomarkers."
The company noted that testicular cancer is the most common form of cancer among young men, with approximately 2,500 new cases in the UK annually and 50,000 survivors requiring post-treatment monitoring.
Dr. Anand Sharma, consultant oncologist at the Mount Vernon Cancer Centre, was quoted saying the accuracy of the test was "unprecedented" and enabled rapid patient advisement.
The company stated that initial patient testing has already begun, with results confirming one patient was clear of cancer while detecting cancer in another patient, allowing for prompt treatment.
EDX Medical also disclosed that while it encountered delays in product availability in the European market affecting current financial year revenue forecasts, these issues have been resolved, and significant revenues from the TC100 service and other products are expected in the following financial period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.